ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase I: At-Home Support for Rural Women Using Group Video Calling

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01672684
Recruitment Status : Completed
First Posted : August 27, 2012
Last Update Posted : October 17, 2014
Sponsor:
Collaborator:
California Breast Cancer Research Program
Information provided by (Responsible Party):
Cheryl Koopman, Stanford University

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This randomized phase I trial studies at-home group video calling sessions in quality of life in rural patients with breast cancer. At-home group video calling support sessions may improve the well-being and quality of life of women who have breast cancer

Condition or disease Intervention/treatment Phase
Depression Post-traumatic Stress Disorder Recurrent Breast Cancer Stage IA Breast Cancer Stage IB Breast Cancer Stage II Breast Cancer Stage IIIA Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer Stage IV Breast Cancer Procedure: support group therapy Other: educational intervention Phase 1

Detailed Description:

PRIMARY OBJECTIVES:

I. To examine whether delivering at-home professionally-led breast cancer support using group video calling is feasible, acceptable and satisfactory for women in rural northern California.

II. To evaluate the feasibility of using on-line tools to recruit, screen, treat, and assess this population for a subsequent randomized clinical trial.

III. Assess whether the rate of recruitment of women in this region in this study using predominantly on-line means of recruitment can be improved over that of the previous study using predominantly face-to-face means of recruitment.

SECONDARY OBJECTIVES:

I. Estimate effect size changes in measures of quality of life (post-traumatic stress disorder symptoms, depression symptoms, perceived stress, and positive states of mind), satisfaction with social support, and self-efficacy for coping with cancer.

II. Prescribe sample size. III. Perform I and II for all of these outcomes.

OUTLINE: Participants are randomized to 1 of 2 treatment arms.

ARM I (experimental arm): Participants complete at-home group video calling sessions for 1 1/2 hours once weekly for 8 weeks.

ARM II (control arm): Participants receive an educational workbook journal.

After completion of study treatment, participants are followed up for 1 week.


Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 34 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Supportive Care
Official Title: At-Home Support for Rural Women Using Group Video Calling
Study Start Date : October 2012
Actual Primary Completion Date : December 2013
Actual Study Completion Date : June 2014

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Arm I (experimental arm)
Participants complete at-home group video calling sessions for 1 1/2 hours once weekly for 8 weeks.
 Procedure: support group therapy
Complete at-home group video calling support sessions
Active Comparator: Arm II (control arm)
Participants receive an educational workbook journal.
 Other: educational intervention
Receive an educational workbook journal
Other Name: intervention, educational


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Feasibility of the study protocol as determined primarily through qualitative analysis of the group sessions and the interview data [ Time Frame: At 1 week post-intervention ]
    The major criterion for determining feasibility is to determine whether we can recruit rural women with breast cancer more rapidly using predominantly on-line procedures in this study than in our previous study that predominantly used face-to-face procedures. The qualitative data for determining the feasibility will be collected during the at-home group video calling sessions and from women's interviews conducted at the end of the study. Will be assessed using mixed methods.

  2. Acceptability of the study protocol as determined primarily through qualitative analysis of the group sessions and the interview data [ Time Frame: At 1 week post-intervention ]
    The qualitative data for determining the acceptability will be collected during the at-home group video calling sessions and from women's interviews conducted at the end of the study. Will be assessed using mixed methods.


Secondary Outcome Measures :
  1. Changes in quality of life (posttraumatic stress, depression symptoms, perceived stress, and positive states of mind) [ Time Frame: From baseline to 1 week post-intervention ]
    Treatment effect size will be estimated for each measure for the purpose of prescribing the sample size for a subsequent larger randomized clinical trial examining efficacy of the intervention. Will be analyzed using generalized linear mixed models.

  2. Changes in satisfaction with social support [ Time Frame: From baseline to 1 week post-intervention ]
    Treatment effect size will be estimated for each measure for the purpose of prescribing the sample size for a subsequent larger randomized clinical trial examining efficacy of the intervention. Will be analyzed using generalized linear mixed models.

  3. Changes in self-efficacy for coping with cancer [ Time Frame: From baseline to 1 week post-intervention ]
    Treatment effect size will be estimated for each measure for the purpose of prescribing the sample size for a subsequent larger randomized clinical trial examining efficacy of the intervention. Will be analyzed using generalized linear mixed models.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • To be eligible for this study, the participant must have been diagnosed with breast cancer within the previous 5 years prior to study entry; individuals who have been diagnosed with any stage of breast cancer are eligible
  • There are no limitations regarding allowable type and amount of prior therapy
  • There are no race/ethnic restrictions
  • There are no life expectancy restrictions
  • Neither Eastern Cooperative Oncology Group (ECOG) nor Karnofsky performance status will be employed
  • There are no requirements for organ and marrow function
  • Ability to understand and the willingness to sign a written informed consent document; this will be assessed in the telephone screen conducted by Lisa Frankel as she will review each section of the consent form with the participant and ask if she has any questions about it; this telephone screen will have been approved by the Stanford University Institutional Review Board (IRB), and Lisa Frankel will conduct the interviews in a private location to ensure confidentiality
  • Eligibility for this study requires that a woman be a resident of one of 27 rural counties in California (Alpine, Amador, Butte, Calaveras, Colusa, Del Norte, El Dorado, Glenn, Imperial, Inyo, Lake, Lassen, Madera, Mariposa, Modoc, Mono, Nevada, Placer, Plumas, Shasta, Sierra, Siskiyou, Sutter, Tehama, Trinity, Tuolumne, or Yuba, except we will not include women living within the following cities: Chico, Madera, Redding, Rocklin, Roseville or Yuba City, due to this study's more rural focus)
  • Eligibility for this study requires that a woman has sufficient hearing to be able to engage in conversation over the phone
  • Eligibility for this study requires that a woman has a private place available where she can access the internet
  • Eligibility for this study requires that a woman is potentially available to meet at the day of the week and time of the day that the group intervention is scheduled â in the event that she is randomly assigned to receive the at-home group calling intervention
  • Eligibility for this study requires that women have broadband or digital subscriber line (DSL) internet access
  • Eligibility for this study requires that women have a computer with a webcam and either a microphone or a phone available to call into the video conference

Exclusion Criteria:

  • There are no therapy restrictions
  • There are no restrictions regarding use of other investigational agents
  • There are no exclusion requirements due to co-morbid disease or incurrent illness
  • Requirements regarding history of allergic reactions attributed to compounds of similar chemical or biologic composition to investigational agent or device are not applicable to this study
  • There are no exclusion criteria relating to concomitant medications or substances that have the potential to affect the activity or pharmacokinetics of the study agent
  • There are no other agent-specific exclusion criteria
  • Pregnancy or nursing patients will not be excluded from the study
  • Patients who are cancer survivors or those who are human immunodeficiency virus (HIV)-positive will not be excluded from the study
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01672684


Locations
United States, California
Sierra Streams Institute
Nevada City, California, United States, 95959
Stanford University Cancer Institute
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
California Breast Cancer Research Program
Investigators
Principal Investigator: Cheryl Koopman Stanford University
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party: Cheryl Koopman, Professor (Research) of Psychiatry and Behavioral Sciences, Stanford University
ClinicalTrials.gov Identifier: NCT01672684     History of Changes
Other Study ID Numbers: BRSADJ0023
NCI-2012-01357 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
21349 ( Other Identifier: Stanford University )
First Posted: August 27, 2012    Key Record Dates
Last Update Posted: October 17, 2014
Last Verified: October 2014

Keywords provided by Cheryl Koopman, Stanford University:
quality of life

Additional relevant MeSH terms:
Breast Neoplasms
Stress Disorders, Traumatic
Stress Disorders, Post-Traumatic
Neoplasms by Site
Neoplasms
 Breast Diseases
Skin Diseases
Trauma and Stressor Related Disorders
Mental Disorders